[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100607172":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":27,"responsibleParty":46,"collaborators":49,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":66,"sex":72,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":10,"studyType":78,"phases":10,"briefSummary":79,"conditions":80,"keywords":84,"overallStatus":29,"whyStopped":10,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"German Heart Institute","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Patients at risk of heart failure",null,"asymptomatic individuals, residing in urban areas in Germany, between the age of 40 to 69 years without known HF and at least one established cardiovascular risk factor",[13],{"name":14,"affiliation":15,"role":16},"Sebastian Kelle, Prof. Dr.","Deutsches Herzzentrum der Charité","PRINCIPAL_INVESTIGATOR",[18,23],{"name":19,"role":20,"phone":21,"phoneExt":10,"email":22},"Prof. Dr. Sebastian Kelle","CONTACT","+493045931182","sebastian.kelle@dhzc-charite.de",{"name":24,"role":20,"phone":25,"phoneExt":10,"email":26},"Dr. Gisela Thiede","+4915209192843","gisela.thiede@dhzc-charite.de",[28],{"facility":15,"status":29,"city":30,"state":10,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"RECRUITING","Berlin","13353","Germany","DE",{"type":35,"coordinates":36},"Point",[37,38],13.41053,52.52437,{"lat":38,"lon":37},[41,43],{"name":42,"role":20,"phone":21,"phoneExt":10,"email":22},"Sebastian Kelle, Prof., MD",{"name":44,"role":20,"phone":45,"phoneExt":10,"email":26},"Gisela Thiede, Dr.","0049 1520 9192843",{"type":16,"investigatorFullName":47,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Sebastian Kelle","Dr. Sebastian Kelle (MD)",[50,53,55,58,60,62],{"name":51,"class":52},"AstraZeneca","INDUSTRY",{"name":54,"class":52},"Philips Healthcare",{"name":56,"class":57},"Deutsches Herzzentrum der Charité, Berlin","UNKNOWN",{"name":59,"class":57},"German Heart Center Foundation",{"name":61,"class":57},"Nationale Herzallianz (NHA)",{"name":63,"class":57},"Deutsche Herzstiftung","100607172","determination-of-the-prevalence-of-unrecognized-heart-failure-among-patients-at-risk-in-urban-areas-across-germany-using-cmr-100607172",false,"NCT07185100","Determination of the Prevalence of Unrecognized Heart Failure Among Patients at Risk in Urban Areas Across Germany Using CMR","A Prospective, Cross-sectional, Nationwide Community-based Observational Study to Determine the Prevalence of Unrecognized Heart Failure Among Patients at Risk in Urban Areas Across Germany Using CMR","WE-CARE-HF-CMR","Inclusion Criteria:\n\nAsymptomatic subjects with:\n\n* chronic diabetes mellitus (known\u002Fdiagnosed and\u002For antidiabetic medication and\u002For elevated HbA1C) and\u002For\n* renal impairment (known\u002Fdiagnosed CKD and\u002For in laboratory CKD III° or higher) and\u002For\n* Hypertension (known\u002Fdiagnosed and\u002For antihypertensive medication\u002Ftreatment) and\u002For\n* Hypercholesterolaemia (known\u002Fdiagnosed and\u002For antilipid medication\u002Ftreatment) and\u002For\n* Obesity (known\u002Fdiagnosed and\u002For BMI \\> 30 (kg\u002Fm²)) and\u002For\n* Smoker (known\u002Fdiagnosed and\u002For current\u002Fprevious and\u002For medication\u002Ftreatment)\n* Age 40-69 years\n* female or male or diverse sex\n* Ability to provide informed consent\n* Provision of Informed Consent\n\nExclusion Criteria:\n\n* Inability to provide written informed consent\n* Diagnosed heart failure or previously detected reduced ejection fraction\n* General MRI exclusion criteria (pacemaker, defibrillator, intracranial aneurysm clips, metallic foreign bodies in the eyes)\n* Any MRI exclusion criteria not listed here, as determined by the MRI laboratory performing the procedure\n* Haemodynamically unstable participants (heart rate \\\u003C 45\u002Fmin, systolic blood pressure \\\u003C 90 mmHg)\n* Claustrophobia\n* Sensorineural hearing loss of 30 dB or more and tinnitus\n* Acute mental disorders requiring therapy\n* In the presence of pregnancy","ALL","40 Years","69 Years",{"count":76,"type":77},600,"ESTIMATED","OBSERVATIONAL","Heart failure (HF) in patients at risk is often overlooked, and when detected, there is a lack of early and effective preventive interventions. The WE-CARE-HF-CMR study, conducted in large cities\u002Fmetropol areas in Germany ( \\> 1.000.000 inhabitants), aims to close this gap by evaluating the feasibility of a mobile, telemedicinemonitored HF-screening approach combining cardiac magnetic resonance imaging (CMR), quality of life assessment and laboratory tests as key elements in asymptomatic patients at risk. WE-CARE-HF-CMR will provide a proposal for a comprehensive, contemporary screening approach for patients at risk to develop HF tailored to the needs of the target population. This will provide important new information on the prevalence of asymptomatic HF in at-risk patients in urban versus rural areas.\n\nThe results of the study will be compared with the results from the \"HERZCheck'' trial, which provides data from approximately 4,500 participants in rural areas in Germany and has already been completed (NCT05122793).",[81,82,83],"Heart Failure With Preserved Ejection Fraction (HFPEF)","Renal Dysfunction","Stage B Heart Failure",[85,86,87,88,89,90,32,91,92,93,94,95,96,97],"Prevention","Heart failure","HFpEF","Asymptomatic","Cardiology","Urban area","CMR","Cardiac Magnetic Resonance","HFrEF","Diastolic Dysfunction","Strain","mobile","GLS","2026-03-26",{"date":100,"type":101},"2026-04-01","ACTUAL",{"date":103,"type":101},"2025-09-13",{"date":105,"type":77},"2036-12-31",{"name":5,"class":6},1]